Advantages of TRUS-based delineation for high-dose-rate prostate brachytherapy planning

被引:4
|
作者
Lavoie-Gagnon, Heloise [1 ]
Martin, Andre-Guy [1 ,2 ]
Poulin, Eric [1 ]
Archambault, Louis [1 ,2 ]
Pilote, Laurie [3 ]
Foster, William [1 ]
Vigneault, Eric [1 ,2 ]
Carignan, Damien [1 ,2 ]
Lacroix, Frederic [1 ]
机构
[1] Univ Laval, CHU Quebec, Dept RadioOncol, 11 Cote Palais, Laval, PQ, Canada
[2] Univ Laval, CHU Quebec, Ctr Rech, Laval, PQ, Canada
[3] Hotel Dieu Levis, Dept RadioOncol, Levis, PQ, Canada
关键词
brachytherapy; prostate cancer; delineation; registration; ultrasound; high-dose-rate; MAGNETIC-RESONANCE; RADICAL PROSTATECTOMY; PENILE STRUCTURES; VOLUME; CT; MONOTHERAPY; RISK; MRI; UNCERTAINTIES; INTERMEDIATE;
D O I
10.5114/jcb.2022.113544
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the variability of prostate contours delineated on computed tomography (CT) and transrectal ultrasound (TRUS). Material and methods: A TRUS-based high-dose-rate (HDR) brachytherapy procedure was introduced in 2016 in our center. The first thirty patients were additionally imaged with CT immediately after the treatment. In 2018, four different radiation oncologists (ROs: 1, 2, 3, 4) contoured the prostate on both modalities. A volume comparison was performed between CT and TRUS imaging. Using prostate gold fiducial makers, a rigid registration between CT and TRUS was done in 20 of the 30 patients studied. Jaccard index (JI) was computed to evaluate the inter-observer volume delineation agreement. Results: The ratio of TRUS/CT volumes was 0.82 (95% CI: 0.79-0.87%). The mean JI was 87% for CT and 92% for TRUS, when comparing all four ROs; CT and TRUS JIs were significantly different (p < 0.001). The mean JI for the pros- tate on CT was significantly more consistent (p < 0.001) when comparing RO1, 2, and 3 together (RO1-2, RO1-3, and RO2-3; mean = 89%) than when comparing RO4 (newest to clinical practice) to others (RO1-4, RO2-4, and RO3-4; mean = 85%). For TRUS planning, the mean JI was not significantly different (p > 0.05) when comparing all ROs. Conclusions: The inter-observer and intra-observer variability were statistically significantly smaller on TRUS compared to CT-based planning, despite varying ROs clinical experiences. The superior soft tissue contrast offered by TRUS obviates the effect of the ROs experience on prostate contour volumes and enables more reproducible prostate delineation.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [21] High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer
    Yoshioka, Yasuo
    Konishi, Koji
    Oh, Ryoong-Jin
    Sumida, Iori
    Yamazaki, Hider
    Nakamura, Satoaki
    Nishimura, Kazuo
    Nonomura, Norio
    Okuyama, Akihiko
    Inoue, Takehiro
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 (01) : 62 - 68
  • [22] High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer
    Zwahlen, Daniel R.
    Andrianopoulos, Nick
    Matheson, Bronwyn
    Duchesne, Gillian M.
    Millar, Jeremy L.
    BRACHYTHERAPY, 2010, 9 (01) : 27 - 35
  • [23] Assessment of Daily Replanning and Geometrical Variation of High-dose-rate Brachytherapy for the Prostate
    Uchida, Hirofumi
    Hirata, Takero
    Otani, Keisuke
    Suzuki, Osamu
    Oda, Michio
    Akino, Yuichi
    Sumida, Iori
    Hatano, Koji
    Fujita, Kazutoshi
    Uemura, Motohide
    Imamura, Ryoichi
    Eino, Daisuke
    Yoshioka, Yasuo
    Nonomura, Norio
    Ogawa, Kazuhiko
    ANTICANCER RESEARCH, 2020, 40 (03) : 1677 - 1682
  • [24] Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy
    Raleigh, David R.
    Hsu, I-Chow
    Braunstein, Steve
    Chang, Albert J.
    Simko, Jeffry P.
    Roach, Mack, III
    BRACHYTHERAPY, 2015, 14 (02) : 185 - 188
  • [25] The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer
    Yoshioka, Yasuo
    Yoshida, Ken
    Yamazaki, Hideya
    Nonomura, Norio
    Ogawa, Kazuhiko
    JOURNAL OF RADIATION RESEARCH, 2013, 54 (05) : 781 - 788
  • [26] Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone
    Kent, Aaron R.
    Matheson, Bronwyn
    Millar, Jeremy L.
    BRACHYTHERAPY, 2019, 18 (03) : 313 - 321
  • [27] Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy - preliminary results
    Jo, Yoshimasa
    Fujii, Tomohiro
    Hara, Ryoei
    Yokoyama, Teruhiko
    Miyaji, Yoshiyuki
    Yoden, Eisaku
    Hiratsuka, Junichi
    Nagai, Atsushi
    BJU INTERNATIONAL, 2012, 109 (06) : 835 - 839
  • [28] Needle migration and dosimetric impact in high-dose-rate brachytherapy for prostate cancer evaluated by repeated MRI
    Buus, Simon
    Lizondo, Maria
    Hokland, Steffen
    Rylander, Susanne
    Pedersen, Erik M.
    Tanderup, Kari
    Bentzen, Lise
    BRACHYTHERAPY, 2018, 17 (01) : 50 - 58
  • [29] Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series
    Thomas, Horatio
    Chen, Jie Jane
    Shaheen, Haitham
    Sabbagh, Ali
    Abdul-Baki, Hasan
    Chau, Oi Wai
    Malik, Nauman
    Ayoub, Alan
    Hassanzadeh, Comron
    Hsu, I-Chow
    Mohamad, Osama
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2024, 16 (01) : 1 - 5
  • [30] Automatic bi-objective parameter tuning for inverse planning of high-dose-rate prostate brachytherapy
    Maree, S. C.
    Bosman, P. A. N.
    van Wieringen, N.
    Niatsetski, Y.
    Pieters, B. R.
    Bel, A.
    Alderliesten, T.
    PHYSICS IN MEDICINE AND BIOLOGY, 2020, 65 (07)